Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates ‘Market Perform’ Rating
On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating.
Cvs Health Corp (CVS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 15,844,972 | $1,194,552,439 | -6% | 3.86% |
| 2. | Glenview Capital Larry Robbins | 8,196,799 | $617,956,677 | 13.76% | |
| 3. | 6,525,800 | $491,980,062 | +41% | 0.07% | |
| 4. | Millennium Management Israel Englander | 5,378,148 | $405,458,578 | +33% | 0.17% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 5,294,134 | $399,124,762 | +71% | 0.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $56.85 | 35 | $1,989.75 | 85 | 2024-10-23 | Filing | |
| $62.24 | 10 | $622.40 | 50 | 2024-10-02 | Filing | |
| $56.47 | 35 | $1,976.45 | 40 | 2024-09-09 | Filing | |
| $63.70 | 1,570 | $100,009.00 | 12,007 | 2025-06-05 | Filing | |
| $66.70 | 30,000 | $2,001,000.00 | 39,356 | 2025-02-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.02 | 7,500 | $532,650.00 | 22,156 | 2025-08-20 | Filing | |
| $66.67 | 150,000 | $10,000,710.00 | 8,196,799 | 2025-05-06 | Filing | |
| $67.99 | 96,999 | $6,595,272.41 | 8,346,799 | 2025-05-05 | Filing | |
| $67.37 | 1,226,933 | $82,654,672.72 | 8,443,798 | 2025-05-05 | Filing | |
| $69.66 | 373,776 | $26,035,591.55 | 9,670,731 | 2025-05-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,127,035 | $327,934,201 | 0.28% | |
| 2. | 2,956,013 | $234,589,192 | 0.32% | |
| 3. | 2,026,761 | $160,843,753 | 3.86% | |
| 4. | 1,899,163 | $150,717,576 | 2.05% | |
| 5. | 725,189 | $57,550,999 | 0.31% |
News See All
Jim Cramer Commented on These 13 Stocks From Different Market Sectors
“Tonight, I want to break down the performance of each major sector in the market for 2025.
Jim Cramer Reveals How CVS Health Corporation (CVS) is "Saving a Lot of Money"
CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical chains in America. Its shares are up by 73% over the past year.
11 Most Undervalued Blue Chip Stocks to Buy Now
As we enter 2026, U.S. equities are expected to enter a phase marked by several complexities following the outsized gains in 2025.
9 Stocks Jim Cramer Talked About
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the impact of the US operation in Venezuela on the stock market.
JPMorgan Names CVS a Top Pick as Turnaround Gains Traction
The stock dropped 43% in 2024, then swung the other way with an 80.5% gain this year. Even after that run, Wall Street still sees room to move.
20 Best Performing Dividend Stocks in 2025
2025 has felt like another strong year for stocks. The S&P 500 is up close to 18% so far.
CVS Gets Higher Target as Bernstein Cites Management Confidence
On December 12, Bernstein raised the firm’s price target on CVS Health Corporation (NYSE:CVS) to $87 from $86 and kept a Market Perform rating after what it described as a very positive Investor Day...
Where is CVS Health Corporation (CVS) Headed According to Analysts?
CVS Health Corporation (NYSE:CVS) is one of the best affordable healthcare stocks to buy now.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.